AI Platforms Will Revolutionize Personalized Biologics And Computational Discovery

AnalystHighTarget

Not Invested

Community Contributor

Published

27 Aug 25

AnalystHighTarget's Fair Value

US$5.00

62.4% undervalued

05 Sep

US$1.88

199.1%

7.4%

199.1%

7.4%

You can edit this narrative until Aug 27 9:28 PM. Then, changes will post as Updates.

Author's Valuation

US$562.4% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$5

62.4% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

18.55%

Life Sciences revenue growth rate

0.31%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.31%

Calculation

CA$15.51m

Earnings '28

55.89x

PE Ratio '28

CA$866.94m

Market Cap '28

CA$866.94m

Market Cap '28

101.40m

No. shares '28

CA$8.55

Share Price '28

CA$8.55 Share Price '28

Discounted to 2025 @ 7.34% p.a.

CA$6.91

Fair Value '25

CA$6.91 Fair Value '25

Converted to USD @ 0.7233 CAD/USD Exchange Rate

US$5.00

Fair Value '25